Trial Profile
Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen (TOLERANT Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Acronyms TOLERANT
- 28 Nov 2022 Status changed from active, no longer recruiting to completed.
- 25 Mar 2020 Status changed from recruiting to active, no longer recruiting.
- 25 Mar 2020 Planned End Date changed from 1 Nov 2022 to 1 Nov 2023.